Neurotherapy as a Complementary Approach for Beta-Thalassemia Intermedia

Abstract

Beta-thalassemia intermedia (β-TI) is a genetic disorder characterized by chronic anaemia resulting from ineffective erythropoiesis. While management typically involves transfusions and pharmacological therapies, these carry risks like iron overload and variable efficacy. Alternative approaches, such as neurotherapy, offer potential for improving haematological outcomes without invasive interventions. The aim of this study was to evaluate the impact of neurotherapy as a complementary treatment in a 44-year-old female patient with β-TI. A 44-year-old female with β-TI underwent 48 neurotherapy sessions over three months (four sessions per week). Therapy targeted specific pressure points to stimulate organ functions critical for haemoglobin synthesis and overall health, including the pancreas, kidneys, thyroid, and liver. Techniques focused on improving erythropoietin production, enhancing iron metabolism, and promoting globin chain synthesis. Following therapy, the patient’s haemoglobin level increased from 5.9 g/dL to 9.7 g/dL, with improvements in haematocrit, MCV, MCH, MCHC and ferritin levels. Platelets, serum TSH and ESR showed significant reductions, while vitamin B12 normalized. Clinically, the patient reported increased energy levels, reduced fatigue, and improved physical activity tolerance. No adverse effects were observed, and the patient expressed high satisfaction with the outcomes. This case highlights the potential of neurotherapy as a safe and effective adjunctive treatment for β-TI. By improving haematological parameters and alleviating fatigue, neurotherapy could serve as a valuable addition to the therapeutic toolkit for managing this condition.